Castle Biosciences unveiled three studies demonstrating that its TissueCypher test offers objective risk assessment beyond routine endoscopic biopsies. In one case, the test identified prevalent high-grade dysplasia in a patient previously classified as low-risk, enabling timely eradication therapy. Another multi-center cohort study highlighted a significant disconnect between traditional clinicopathologic scoring and molecular findings, with 96% of clinicians altering patient management plans based on TissueCypher results.
In section Releases
Molecular Testing Reveals Hidden Risks in Barrett’s Esophagus Patients
Standard biopsy results often fail to capture the true biological risk of progression in patients with Barrett’s esophagus, according to new data presented at the American College of Gastroenterology 2026 Annual Scientific Meeting. Findings suggest that molecular profiling can identify high-risk cases that traditional histopathology misses entirely.
Dr. Virendra Joshi of Emory University noted that biopsy findings do not always reflect a patient’s individual risk of developing esophageal adenocarcinoma. By analyzing protein biomarkers and tissue architecture, TissueCypher provides a five-year probability of disease progression. This precision allows physicians to move beyond generalized surveillance intervals, opting for either earlier interventions or extended monitoring based on the specific molecular signature of the tissue. These results further emphasize the role of spatialomics in refining treatment pathways for precancerous esophageal conditions.
Comments (0)
No comments yet. Be the first!